RecruitingNCT06647888

Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia

A Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Enavogliflozin in Patients With Type II Diabetes Mellitus Accompanied by Hypertension or Dyslipidemia

Sponsor

Daewoong Pharmaceutical Co. LTD.

Enrollment

12,000 participants

Start Date

Dec 3, 2024

Study Type

OBSERVATIONAL

Conditions

Diabetes Mellitus, Type 2

Summary

This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking how well a combination diabetes medication — enavogliflozin with or without metformin — works in real-world patients who also have high blood pressure or high cholesterol. Researchers will follow patients in normal clinical care to collect data on safety and effectiveness. **You may be eligible if...** - You are 19 or older - You have type 2 diabetes with high blood pressure or high cholesterol - You are already taking or about to start enavogliflozin (Envlo Tab or Envlomet SR Tab) - You agree to participate and provide written consent **You may NOT be eligible if...** - You have already taken this specific medication combination before - You are expected to need insulin during the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.